

Table SII. Cyclosporine administration schedule and outcomes in patients with solar urticaria

Patient (sex; age, years)	CsA dosage, mg/kg/day; duration	Clinical outcome	MUD before CsA, J/cm ² (action spectrum)	MUD after CsA, J/cm ² (action spectrum)	Adverse events due to CsA
1 (F; 44)	4; 3 months	Unchanged	2 (UVA) <0.5 (UVB)	ND	None
2 (F; 28)	3; 3 months, then 5; 3 months	Unchanged	0.5 (UVA) 0.03 (UVB)	ND	Acne
3 (F; 37)	3; 2 weeks	Unchanged	1 (UVA) 0.18 (UVB)	ND	Chest oppression
4 (M; 47)	2.5; 1 month, then 5; 1.5 months	Unchanged	0.6 (UVA) 0.03 (UVB)	ND	None
5 (F; 34)	4; 1 month	Unchanged	0.8 (UVA)	ND	Nausea, myalgia, arthralgia, paraesthesia, severe asthenia
6 (F; 40)	2.5; 1 month, then 3; 4 months	Unchanged	6 (UVA)	3 (UVA)	None
7 (F; 25)	2.5; 4 months, then 5; 7 months	CR; relapse 1 month after CsA withdrawal	1 (UVA) 0.1 (UVB)	>8 (UVA) >0.18 (UVB)	None
8 (F; 39)	5; 3 months	Unchanged	24 (UVA) 4.8 (UVB) 0.03 (polyC)	0.03 (polyC)	Nausea, acne
9 (M; 47)	2.5; 7 months, then 3; 2 months	PR	5.6 (UVA)	>20 (UVA)	None
10 (F; 51)	5; 1 month	Unchanged	8 (UVA)	4 (UVA)	Abdominal pain, diarrhoea, gingival hypertrophy
11 (M; 23)	5; 1 month	Unchanged	2 (UVA)	1.5 (UVA)	None

MUD: minimal urticarial dose; UV: ultraviolet; polyC: polychromatic solar spectrum including 95% UVA and 5% UVB; ND: not done; CR: complete remission; PR: partial response.